RESIQUIMOD Chemical Properties

Melting point:

190-193°

Boiling point:

553.6±50.0 °C(Predicted)

Density 

1.28

storage temp. 

-20°C

solubility 

DMSO: soluble10mg/mL, clear (warmed to 60 °C)

form 

powder

pka

14.63±0.29(Predicted)

color 

white to tan

λmax

325nm(lit.)

Merck 

14,8151

Stability:

Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 2 months.

InChIKey

BXNMTOQRYBFHNZ-UHFFFAOYSA-N

Safety Information

WGK Germany 

3

RTECS 

NJ5911320

HS Code 

2933998090

RESIQUIMOD Usage And Synthesis

Description

Resiquimod (CAS 144875-48-9) is a Toll-like receptor 7/8 agonist.1 May be used as an immune adjuvant in cancer vaccines.2 Resiquimod-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release.3 Topical treatment of wild-type mice induces systemic autoimmune disease which may be used as a model of systemic Lupus erythematosus.4? It displayed potent antiviral activity (EC50 = 23.5 nM) in a murine norovirus replicon model.5

Uses

Resiquimod is an imidazoquinoline derivative that acts as an immune response modifier. Resiquimod shows antitumor and antiviral activity and is used in the treatment of skin lesions such as herpes simplex virus. Resiquimod is a toll-like receptor 9 (TLR7) agonist.

Uses

Resiquimod has been used in the stimulation of bone marrow-derived dendritic cells (BMDCs) stimulation( and B cells. It has also been used as a ligand for toll-like receptors (TLR7) in malignant melanoma cell line B16F10.

Definition

ChEBI: Resiquimod is an imidazoquinoline.

Biochem/physiol Actions

Resiquimod belongs to the class of imidazoquinolinamines compounds with immunomodulatory effects. Resiquimod increases the levels of cytokines such as TNF-α, IL-6 and IFN-α.

storage

Store at +4°C

References

1) Jurk et al. (2002), Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848; Nat. Immunol., 3 499 2) Sabado et al. (2015), Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma; Cancer Immunol. Res., 3 278 3) Ilyinskii et al. (2014), Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release; Vaccine, 32 2882 4) Yokogawa et al. (2014), Epicutaneous application of toll-like receptor 7 agonists leads to systemic autoimmunity in wild-type mice: a new model of systemic Lupus erthematosus; Arthritis Rheumatol., 66 694 5) Tuipulotu et al. (2018), TLR7 Agonists Display Potent Antiviral Effects against Norovirus Infection via Innate Stimulation; Antimicrob. Agents Chemother., 62 e02417

RESIQUIMOD(144875-48-9)Related Product Information

• Retinoic acid
• Sunitinib Malate
• Zafirlukast
• Etoposide
• GLYX 13
• Imiquimod
• 5-AZABENZIMIDAZOLE
• 3H-IMIDAZO[4,5-C]PYRIDINE
• 2-METHYLIMIDAZO[4,5-C]PYRIDINE
• RESIQUIMOD
• 1-(2-METHYLPROPYL)-1H-IMIDAZO[4,5-C]QUINOLINE
• 4-Chloro-1-(2-methylpropyl)-1H-imidazo[4,5-c]quinoline
• 1H-Imidazo[4,5-c]pyridine,1-ethyl-